Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > NY-ESO-1

NY-ESO-1

Brief Information

Name:Cancer/testis antigen 1
Target Synonym:CTAG1A more,Autoimmunogenic cancer/testis antigen NY-ESO-1,LAGE2A,CTAG1,CTAG1A,CTAG1B,Cancer/Testis Antigen 1B,Cancer/Testis Antigen 6.1,L Antigen Family Member 2,Cancer/Testis Antigen 1,LAGE-2,LAGE2B,CT6.1,CTAG,ESO1,Cancer Antigen 3,NY-ESO-1,LAGE2,New York Esophageal Squamous Cell Carcinoma 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
CHEK-STP114 Human NY-ESO-1 specific TCR-HEK293 cell line
ACRO Quality

Part of Bioactivity data

CHEK-STP114-Cell-based assay
 NY-ESO-1 FACS

FACS analysis NY-ESO-1 specific TCR on NY-ESO-1 specific TCR-HEK293 cell line.
FACS assay shows that PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein can bind to NY-ESO-1 specific TCR-HEK293 cell line. NY-ESO-1 specific TCR-HEK293 cell line was red line, Negative control HEK293 cells was grey line (QC tested).

Synonym Name

NY-ESO-1

Background

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Cancer vaccine NY-ESO-1 (Ludwig Institute/Peking University/Jewim Pharmaceutical) Phase 2 Clinical Ludwig Institute For Cancer Research Liver Neoplasms; Melanoma Details
Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio) Phase 2 Clinical Shenzhen Bindebio Ltd Stomach Neoplasms; Esophageal Neoplasms; Glioma; Carcinoma, Hepatocellular Details
Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI) Phase 1 Clinical Albert Einstein College Of Medicine Inc, National Cancer Institute Neoplasms Details
Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell) CD8-TCR-T cells; NY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cells Phase 2 Clinical Roswell Park Cancer Institute Neoplasms Details
LYL-132 LYL-132; GSK-4427296 Phase 1 Clinical Lyell Immunopharma Inc Solid tumours; Neoplasms Details
GSK-3845097 GSK-3845097; GSK3845097 Glaxosmithkline Plc Details
GSK-3901961 GSK-3901961; GSK3901961 Glaxosmithkline Plc Details
HBI-0201-ESO TCRT HBI-0201-ESO TCRT Phase 2 Clinical Hadassah Medical Organization Ovarian Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Sarcoma, Synovial; Sarcoma; Neuroblastoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis Details
mipetresgene autoleucel TBI-1301 Phase 2 Clinical Takara Bio Inc Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Lung Neoplasms; Melanoma Details
NY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute) Phase 1 Clinical Roswell Park Cancer Institute Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
NY-ESO-1 TCR Phase 2 Clinical Kite Pharma, National Cancer Institute Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Sarcoma, Synovial; Sarcoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Meningioma Details
Letetresgene autoleucel GSK-3377794; GSK-794 Phase 2 Clinical Adaptimmune Llc Ovarian Neoplasms; Neoplasms; Multiple Myeloma; Melanoma Details
TCR Affinity Enhancing Specific T cell Therapy TAEST-16001 Phase 2 Clinical Guangzhou Xiangxue Pharmaceutical Co Ltd, Guangzhou Institute Of Respiratory Health Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Urinary Bladder Neoplasms; Osteosarcoma; Sarcoma; Breast Neoplasms; Bone Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Rasdegafusp alfa CDX-1401 Phase 2 Clinical Ludwig Institute For Cancer Research Prostatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Skin Melanoma; Brain Neoplasms; Oligodendroglioma; Urinary Bladder Neoplasms; Neoplasms; Glioblastoma; Colonic Neoplasms; Leukemia, Myelomonocytic, Chronic; Anemia, Refractory; Myelodysplastic Syndromes; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms Details
MT-601 MT601 Phase 1 Clinical Marker Therapeutics Inc Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
Autologous NY-ESO-1-targeting dendritic cell vaccine (Roswell Park Cancer Institute) DEC-205-NY-ESO-1; vCP2292; VCP-2292 Phase 2 Clinical Roswell Park Cancer Institute Ovarian Neoplasms; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message